Home » Clinical Trials » Search Clinical Trials
Therapeutic Areas: Oncology | Nephrology/Urology
Clinical Trials: Bladder Cancer
A listing of clinical trials currently looking for volunteers to enroll in Bladder Cancer studies. Click on the closest city to find more detailed information on a research study in your area.
Phoenix : Arizona Oncology Associates, P.C., Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Tucson : Arizona Clinical Research Center, Inc. Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Duarte : City of Hope Updated
Bladder Cancer Database
View More »
Anaheim : Pacific Cancer Medical Inc. Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Bakersfield : Comprehensive Blood and Cancer Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Fountain Valley : Compassionate Cancer Care Medical Group, Inc Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Fullerton : Saint Jude Heritage Medical Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Los Angeles : University of California Los Angeles Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Mission Hills : North Valley Hematology Oncology Medical Group Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Orange : Medical Oncology Care Associates Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Palo Alto : VA Palo Alto Health Care System
Fiber-Optic Confocal Microscopy of the Urinary Tract Histopathology
Redondo Beach : Cancer Care Associates Medical Group, Inc. Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Santa Maria : Central Coast Medical Oncology Group Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Stanford : Stanford University School of Medicine
Phase II Pazopanib in Combination With Weekly Paclitaxel in Refractory Urothelial Cancer
Stockton : Stockton Hematology Oncology Medical Group, Inc Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Denver : The Urology Center of Colorado
Evaluating EN3348 compared to Mitomycin C for treatment of non-muscle invasive bladder cancer
Denver : The Urology Center of Colorado Updated
Phase II, open-label study evaluating DN24-02 as adjuvant therapy in subjects with high risk HER2+ urothelial carcinoma.
Denver : The Urology Center of Colorado
Phase III, double blinded, placebo-controlled, randomized trial evaluating the efficacy and safety of multiple instillations of intravesical therapy vs. placebo in patients with low-intermediate risk of non-muscle invasive bladder cancer.
View More »
Denver : Rocky Mountain Cancer Center - Midtown Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Grand Junction : Saint Mary Regional Cancer Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Middlebury : Connecticut Clinical Research Center
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
New Haven : Yale University, Comprehensive Cancer Center
Trial of Gemcitabine, Carboplatin, and Sorafenib in Chemotherapy-Naive Patients With Advanced/Metastatic Bladder Carcinoma
Stamford : Hematology Oncology Associates, PC Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Ocala : Ocala Oncology Center Pl Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Tampa : H. Lee Moffitt Cancer Center and Research Institute
Oral Lenalidomide and Intravesical BCG for Therapy of Bladder Cancer
Atlanta : The Emory Clinic
Hexvix Cystoscopy for Detection of Bladder Cancer
Coeur d'Alene : North Idaho Urology
Efficacy and Safety of Multi-Instillations of Apaziquone in Patients With Non-Muscle Invasive Bladder Cancer
Elgin : Sherman Health
Metastatic Bladder
View More »
Chicago : The University of Chicago
Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit
Joliet : Joliet Oncology-Hematology Associates, Ltd. Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Quincy : Quincy Medical Group Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Cedar Rapids : Iowa Blood & Cancer Care Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Paducah : Purchase Cancer Group Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Baltimore : The Johns Hopkins Medical Institutions
Incontinent Urinary Diversion Using an Autologous Neo-Urinary Conduit
Bethesda : National Cancer Institute
Safety Study of MGAH22 in HER2-positive Carcinomas
Ann Arbor : University of Michigan
Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy
Detroit : Henry Ford Health System Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Minneapolis : Minnesota Oncology Associates, PC Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Billings : Billings Clinic Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Henderson : Comprehensive Cancer Centers of Nevada (TORI) Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Las Vegas : Comprehensive Cancer Centers of Nevada Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Lebanon : Dartmouth Hitchcock Medical Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Lawrenceville : AdvanceMed Research
Bladder Cancer
View More »
Basking Ridge : Memorial Sloan-Kettering at Basking Ridge
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Somerville : Somerset Urological Associates, PA
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Lake Success : Biomedical Research Alliance of New York
Locally Advanced/Metastatic Urothelial Tract or Bladder Cancer - Adults
New Hyde Park : The Arthur Smith Institute for Urology
EN3348 As Compared With Mitomycin C in the Treatment of BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer
View More »
Albany : New York Oncology Hematology Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Commack : Memorial Sloan-Kettering Cancer Center @ Suffolk
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Lake Success : Monter Cancer Center, North Shore LIJ Health Systems Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
New York : Memorial Sloan Kettering Cancer Center
Gemcitabine and Split-Dose Cisplatin Plus Everolimus (RAD001) in Patients With Advanced Solid Tumor Malignancies
New York : Memorial Sloan-Kettering Cancer Center
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
New York : Herbert Irving Pavillion 11th Floor
Phase I & II Trial of Intravesicular Abraxane for Treatment-refractory Bladder Cancer
New York : Memorial Sloan Kettering Cancer Center
RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder
New York : Mount Sinai Medical Center
Trial of Amrubicin as Second-Line Therapy in Patients With Advanced/Metastatic Refractory Urothelial Carcinoma
Rockville Centre : Memorial Sloan-Kettering Cancer Center at Mercy Medical Center
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Sleepy Hollow : Memoral Sloan Kettering Cancer Center@Phelps
Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer
Staten Island, : Male and Female Urology
Efficacy and Safety Study of Apaziquone vs. Placebo in Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)
Winston-Salem : Piedmont Hematology Oncology Associates, PLLC Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Canton : Gabrail Cancer Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Cincinnati : University of Cincinnati Physician's Inc. Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Bend : Saint Charles Medical Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Eugene : Willamette Valley Cancer Institute and Research Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Memphis : The West Clinic Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Nashville : Sarah Cannon Research Institute
Safety Study of MGA271 in Refractory Cancer
Nashville : Sarah Cannon Research Institute
Safety Study of MGAH22 in HER2-positive Carcinomas
Nashville : Vanderbilt University Medical Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Houston : S. R. Burzynski Clinic
Phase II Study Of Antineoplastons A10 And AS2-1 In Patients With Carcinoma Of The Bladder
View More »
Bedford : Texas Oncology - Bedford Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Dallas : Mary Crowley Medical Research Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Galveston : University of Texas Medical Branch Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Houston : UT MD Anderson Cancer Center
Computed Tomography Urography (CTU) vs Intravenous Urography (IVU) on Patients at Risk of Urothelial Tumors
Houston : UT MD Anderson Cancer Center
Phase IB Intravesical Administration of SCH 721015
Midland : Allison Cancer Center Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Norfolk : Virginia Oncology Associates Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Salem : Oncology & Hematology Associates of Southwest Virginia, Inc Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Tacoma : Northwestern Medical Specialists, PLLC Updated
Study of ACE-011 to Determine Safe and Effective Dose of ACE-011 for the Treatment of Chemotherapy Induced Anemia in Patients With Advanced Non-small Cell Lung Cancer
Vancouver : Northwest Cancer Specialists Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Znojmo : Nemocnice Znojmo
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Paris : Hôpital Européen Georges Pompidou - Service Oncologie Médicale
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Aachen : Universitaetsklinikum Aachen Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Hamburg : Universitaetsklinikum Hamburg-Eppendorf Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Hamburg : Universitaetsklinik Hamburg-Eppendorf, Med. Klinik II Onkologie, Haematologie
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Homburg/Saar : Saarland University
Adjuvant Versus Progression-Triggered Gemcitabine Monotherapy for Locally Advanced Bladder Cancer
Wiesbaden : Gemeinschaftspraxis fuer Haematologie Onkologie Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Torino : Azienda Ospedaliero Universitaria "San Giovanni Battista di Torino"
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Seoul : Seoul National University Hospital
Safety Study of MGAH22 in HER2-positive Carcinomas
Maastricht : Academisch Ziekenhuis Maastricht Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Nijmegen : Department of Urology, UMC St. Radboud
Longer-term Recurrence Rates in Patients With Bladder Cancer After Hexvix (Cysview)Fluorescence Cystoscopy/TURB
Lublin : SPSK1 Klinika Hematologii
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Bucuresti : Centrul de Diagnostic si Tratament Euromedic Fundeni
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Barcelona : H de La Santa Creu i Sant Pau Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Barcelona : Hospital Clinic i Provincial de Barcelona
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Madrid : Centro Integral Oncologico Clara Campal Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Madrid : Centro Oncologico MD Anderson International España Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Madrid : HU Ramon y Cajal Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Genolier : IMO Clinique de Genolier
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
Glasgow : Beatson West of Scotland Cancer Centre Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Leicester : Leicester Royal Infirmary NHS Trust Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Manchester : The Christie Updated
Eribulin Mesylate Administered in Combination With Gemcitabine Plus Cisplatin Versus Gemcitabine Plus Cisplatin Alone as First-Line Therapy for Locally Advanced or Metastatic Bladder Cancer
Rotherham : The Rotherham NHS Foundation Trust - Dept. of Haematology
Multi-level Evaluation of Chemotherapy-induced Febrile Neutropenia Prophylaxis, Outcomes, and Determinants With Granulocyte-colony Stimulating Factor
